Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, pursuant to the Answer to 21 March 2018 to Question 133791, what the outcome was of recent discussions with the National Institute for Health and Care Excellence with reference to access to Orkambi for people with cystic fibrosis.

The National Institute for Health and Care Excellence (NICE) has procedures in place to review published technology appraisal guidance to determine whether there is significant new evidence that might call for its guidance to be updated. Departmental officials have had a number of discussions with NICE concerning its appraisal of Orkambi for the treatment of cystic fibrosis and NICE next plans to review its guidance in July 2019, but will bring forward the review date if significant new evidence comes to light before that date that might affect its recommendations.